CCL
68
6
CTAS
36
8
LB
16
9
AMP
43
2
MPC
28
3
HIG
48
5
MMC
46
5
TGT
35
4
O
26
16
CTSH
55
3
CA
19
6
QRVO
16
-6
SJM
17
5
OXY
42
17
DTE
49
16
XRX
48
2
AMGN
42
14
CHD
34
7
GIS
47
13
ALL
37
3
CCL
68
6
CTAS
36
8
LB
16
9
AMP
43
2
MPC
28
3
HIG
48
5
MMC
46
5
TGT
35
4
O
26
16
CTSH
55
3
CA
19
6
QRVO
16
-6
SJM
17
5
OXY
42
17
DTE
49
16
XRX
48
2
AMGN
42
14
CHD
34
7
GIS
47
13
ALL
37
3
Financhill
Back

Sangamo Therapeutics 10K Form

Buy
57

SGMO
Sangamo Therapeutics

Last Price:
$2.48
Seasonality Move:
11.45%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SGMO News And Ratings

See the #1 stock for the next 7 days that we like better than SGMO

SGMO Financial Statistics

Sales & Book Value

Annual Sales: $176.2M
Cash Flow: $11.6M
Price / Cash Flow: 0
Annual Sales: $0.19
Price / Book: 13.25

Profitability

EPS (TTM): -0.75000
Net Income (TTM): $-134.8M
Gross Margin: $0
Return on Equity: -199.86%
Return on Assets: -93.87%

Sangamo Therapeutics Earnings Forecast

Key Sangamo Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 18 years for SGMO is 0.00%.
  • The Selling, General & Administrative Expenses for SGMO have been equal to 34.71% of Gross Profit Margin.
  • The Research & Development expenses have been 132.81% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of SGMO is -146.30% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 7 years.

Sangamo Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SGMO
CUSIP: 800677
Website: sangamo.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.35
Quick Ratio: 1.15

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SGMO Technical Analysis vs Fundamental Analysis

Buy
57
Sangamo Therapeutics (SGMO) is a Buy

Is Sangamo Therapeutics a Buy or a Sell?